Clinical Trial Detail

NCT ID NCT03690388
Title A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Exelixis
Indications

thyroid gland cancer

Therapies

Cabozantinib

Age Groups: child adult senior

No variant requirements are available.